Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Soluble egg antigen of *Schistosoma japonicum* (Sj SEA) is a complex mixture of proteins and glycoproteins secreted by the eggs of the parasitic flatworm *Schistosoma japonicum*. It possesses potent immunomodulatory properties, primarily driving a Th2-biased immune response and promoting the expansion of regulatory T cells (Tregs). Sj SEA has been investigated in preclinical research for its potential therapeutic applications in suppressing transplant rejection (such as in skin transplantation models) and treating autoimmune or inflammatory conditions like type 2 diabetes, colitis, and rheumatoid arthritis. However, it is also a major pathogenic factor in schistosomiasis, associated with liver fibrosis and potentially promoting colorectal cancer progression through the activation of oncogenic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on soluble egg antigen of Schistosoma japonicum.